Medical Genetics

Genetics, Biology, and Finding the Exact Diagnosis

At a Glance

X-linked intellectual disability-hypotonia-movement disorder is an umbrella term rather than one diagnosis. Chromosomal microarray, exome or genome sequencing, and trio testing can identify the specific gene, clarify inheritance, and guide monitoring and care.

While “X-linked intellectual disability-hypotonia-movement disorder” describes what a doctor sees, it is not a single disease. It is a clinical “umbrella” that covers several distinctly different genetic conditions ^[1]. Finding the exact gene responsible is the key to moving from a general description to a specific care plan.

The Biology of X-Linked Inheritance

This condition is called “X-linked” because the gene involved is located on the X chromosome. Females have two X chromosomes, while males have one X and one Y.

The “Backup” System: Females have two X chromosomes, and due to a process called X-inactivation, if one has a genetic change, the other may compensate. This is why some mothers are “carriers”—they carry the genetic variant but may have no symptoms. However, depending on the gene and variant mechanism, females can also be clinically affected ^[2]^[3].
The Impact on Males: Males do not have a second X chromosome to act as a backup. If their single X chromosome has a pathogenic variant in one of these critical genes, they are highly likely to develop symptoms of the syndrome, though severity can vary widely ^[4].
Occurrence: Not every case is inherited from a parent. Many are de novo, meaning the change happened randomly in the child for the first time ^[5].

Finding the Specific Gene

Because many different genes can cause the same “triad” of symptoms, doctors use a step-by-step testing process to find the culprit ^[6]. Depending on current professional guidelines, testing may include:

Chromosomal Microarray (CMA): This looks for large missing or extra pieces of genetic material ^[7].
Whole Exome Sequencing (WES) or Genome Sequencing: This is a deep dive into the DNA. The diagnostic yield varies substantially by cohort, test, and analysis method, but it is often used as a first- or second-line test ^[8].
Trio Testing: Testing the child and both parents at the same time is often helpful. It helps doctors quickly see if a genetic change is new (de novo) or passed down, which makes the results easier to interpret ^[9].

Conditions Under the Umbrella

Identifying the exact gene changes the “name” of the condition and tells your care team exactly what to monitor.

Allan-Herndon-Dudley Syndrome (AHDS): Caused by a change in the SLC16A2 (also called MCT8) gene. This is unique because it affects how thyroid hormone gets into the brain ^[10].
BPAN (Beta-propeller Protein-Associated Neurodegeneration): Caused by the WDR45 gene. It often starts with developmental delays and seizures in childhood, but may progress to more stiffness (parkinsonism) in early adulthood ^[11].
DDCH (Deafness-Dystonia-Central Hypomyelination): Caused by the BCAP31 gene. As the name suggests, hearing loss is a major feature that requires early screening ^[12].
IQSEC2-related disorders: These often involve intellectual disability alongside repetitive movements (stereotypies) and a specific type of shaky gait (ataxia) ^[13].

Why the Exact Name Matters

Once the gene is identified, management becomes much more targeted:

Targeted Screening: If SLC16A2 is found, doctors must monitor thyroid levels (specifically T3 and T4), as these children often have high T3 levels that can stress the heart and muscles ^[10]^[14].
Targeted Treatments: For example, Tiratricol is indicated by some regulators specifically for MCT8/SLC16A2 deficiency-related peripheral thyrotoxicosis in specified patients; it is not a general treatment for “thyroid problems” or neurologic disease in all children with an X-linked movement disorder, and treatment decisions belong with an endocrinologist ^[15].
Informed Therapy: Knowing if a condition involves a “biphasic” course (changing over time, like in BPAN) helps therapists prepare for future needs ^[11].

Your Genetic Report Checklist

When you receive a genetic report, look for these key pieces of information to ensure it is complete:

Gene Name: (e.g., SLC16A2, WDR45).
Reference Transcript, Variant and Zygosity: A code like c.1522C>T that describes exactly where the change in the DNA is located ^[16]. You might also see “hemizygous,” which simply describes the number of variant copies (one copy on the single X chromosome in a male).
Inheritance: Does it say “De novo” (new), or “Maternally inherited”? ^[17].
Laboratory Classification and Evidence: This should be classified as Pathogenic or Likely Pathogenic for a diagnosis to be confirmed ^[18]^[19].

Note: If the report lists a “Variant of Uncertain Significance” (VUS), it means there is not enough evidence to establish or rule out the diagnosis. A VUS should not be used alone to guide treatment or predictive testing.

Common questions in this guide

What does an X-linked result mean for my child and our family?

An X-linked result means the relevant gene is on the X chromosome. A boy has one X chromosome, so a pathogenic variant there is more likely to cause symptoms; a girl may have no symptoms or may be affected because X-inactivation can differ between cells. The variant may be inherited from a mother who carries it or may be de novo, meaning it began in the child.

Which genetic tests can identify the cause of this syndrome?

Testing may include chromosomal microarray to look for large missing or extra pieces of DNA, and whole-exome or genome sequencing to examine many genes. Testing the child and both parents together, called trio testing, can show whether a variant is new or inherited and make results easier to interpret. The best testing sequence depends on the clinical genetics team and current guidelines.

What information should I look for in my child's genetic report?

A report should identify the gene, reference transcript, exact variant, and zygosity, which describes how many copies carry the variant. It should state whether the variant is de novo or inherited and give a laboratory classification such as pathogenic, likely pathogenic, or variant of uncertain significance. In a male, hemizygous means the change is present on his single X chromosome.

What does a variant of uncertain significance mean?

A variant of uncertain significance, or VUS, is a genetic change for which there is not enough evidence to determine whether it causes the condition. It should not by itself confirm or rule out the diagnosis or guide treatment and predictive testing. The genetics team may use family testing, new evidence, or future reanalysis to clarify it.

How can finding the exact gene change my child's monitoring or treatment?

Different genes under this umbrella can require different monitoring and may cause different changes over time. For example, SLC16A2-related MCT8 deficiency calls for thyroid monitoring that includes T3 and T4, BPAN may involve stiffness or parkinsonism later, and BCAP31-related DDCH calls for early hearing screening. For specified patients with MCT8/SLC16A2 deficiency-related peripheral thyrotoxicosis, an endocrinologist may consider tiratricol; it is not a general treatment for all X-linked movement disorders.

Should my child have trio testing after exome sequencing?

Trio testing examines the child and both parents at the same time. It can show whether a variant is de novo or inherited and may help the laboratory decide how much weight to give the finding. Ask the clinical genetics team whether it would clarify an existing result or whether reanalysis is more useful.

What should we do if my child's first genetic test is negative?

A negative result may mean that the current test or analysis did not find a cause; it does not always rule out a genetic condition. Ask the clinical genetics team whether the data should be reanalyzed as scientific knowledge and testing methods change and whether additional testing, including trio sequencing, is appropriate.

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on X-linked intellectual disability-hypotonia-movement disorder syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Curated prompts to bring to your next appointment.

1.Based on my child's genetic report, does he have a 'de novo' mutation or is this an inherited X-linked condition?
2.If the report lists a 'Variant of Uncertain Significance' (VUS), what additional information or tests do we need to reach a definitive diagnosis?
3.Does my child's specific gene result suggest we should monitor for other issues, like the thyroid problems seen in MCT8 deficiency or the late-onset stiffness seen in BPAN?
4.Should we consider 'trio' testing (testing both parents along with our child) to help clarify the results of his exome sequencing?
5.Now that we have this specific genetic name, are there any disease-specific clinical trials or registries we should join?

Key takeaways

X-linked intellectual disability-hypotonia-movement disorder is an umbrella term for several genetic conditions, so the exact gene can change the diagnosis and care plan.
A pathogenic variant on a child's X chromosome may be inherited from a carrier mother or arise de novo, and females may be unaffected, mildly affected, or significantly affected.
Chromosomal microarray, whole-exome or genome sequencing, and trio testing are among the tools used to find the responsible gene and clarify inheritance.
A genetic report should list the gene, reference transcript, variant and zygosity, inheritance, and laboratory classification; a VUS does not confirm or rule out the diagnosis.
Gene-specific findings guide monitoring, such as T3 and T4 testing for SLC16A2-related MCT8 deficiency and hearing screening for BCAP31-related DDCH.

References (19)

1
Biallelic MED27 variants lead to variable ponto-cerebello-lental degeneration with movement disorders.
Maroofian R, Kaiyrzhanov R, Cali E, et al.
Brain : a journal of neurology 2023; (146(12)):5031-5043 doi:10.1093/brain/awad257.
PMID: 37517035
2
Phenotypic and genotypic characterization of glucose-6-phosphate dehydrogenase deficiency in Argentina. Retrospective and descriptive study.
Eandi Eberle S, Pepe C, Chaves A, et al.
Archivos argentinos de pediatria 2019; (117(4)):263-270 doi:10.5546/aap.2019.eng.267.
PMID: 31339274
3
[X-linked intellectual disability syndrome with macrocephaly due to BRWD3 gene deletion].
Arroyo-Carrera I, Romero-Peguero R, Martín-Fernández R, et al.
Revista de neurologia 2024; (78(11)):323-326 doi:10.33588/rn.7811.2024057.
PMID: 38813790
4
Two novel DNA variants associated with glucose-6-phosphate dehydrogenase deficiency found in Argentine pediatric patients.
Chaves A, Eberle SE, Defelipe L, et al.
Clinical biochemistry 2016; (49(10-11)):808-10.
PMID: 26827633
5
NEXMIF encephalopathy: an X-linked disorder with male and female phenotypic patterns.
Stamberger H, Hammer TB, Gardella E, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(2)):363-373 doi:10.1038/s41436-020-00988-9.
PMID: 33144681
6
Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists (CCMG).
Carter MT, Srour M, Au PB, et al.
Journal of medical genetics 2023; (60(6)):523-532 doi:10.1136/jmg-2022-108962.
PMID: 36822643
7
Exome and genome sequencing for pediatric patients with congenital anomalies or intellectual disability: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG).
Manickam K, McClain MR, Demmer LA, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2021; (23(11)):2029-2037 doi:10.1038/s41436-021-01242-6.
PMID: 34211152
8
Diagnostic and clinical utility of exome sequencing and chromosomal microarray in children with GDD/iD: a meta-analysis.
Tengsujaritkul M, Louthrenoo O, Likhitweerawong N, et al.
Annals of medicine 2026; (58(1)):2609424 doi:10.1080/07853890.2025.2609424.
PMID: 41472336
9
Genetic testing and analysis of 1024 children with global developmental delay or intellectual disability: a single-center cohort study.
Wang B, Ji X, Wu F, et al.
European journal of pediatrics 2026; (185(7)).
PMID: 42250153
10
Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations.
Remerand G, Boespflug-Tanguy O, Tonduti D, et al.
Developmental medicine and child neurology 2019; (61(12)):1439-1447 doi:10.1111/dmcn.14332.
PMID: 31410843
11
Quantitative retrospective natural history modeling of WDR45-related developmental and epileptic encephalopathy - a systematic cross-sectional analysis of 160 published cases.
Saffari A, Schröter J, Garbade SF, et al.
Autophagy 2022; (18(7)):1715-1727 doi:10.1080/15548627.2021.1990671.
PMID: 34818117
12
Schimke XLID syndrome results from a deletion in BCAP31.
Louie RJ, Collins DL, Friez MJ, et al.
American journal of medical genetics. Part A 2020; (182(9)):2168-2174 doi:10.1002/ajmg.a.61755.
PMID: 32681719
13
Differences in Expression of IQSEC2 Transcript Isoforms in Male and Female Cases with Loss of Function Variants and Neurodevelopmental Disorder.
Baladron B, Mielu LM, López-Martín E, et al.
International journal of molecular sciences 2022; (23(16)) doi:10.3390/ijms23169480.
PMID: 36012761
14
Clinical and genetic characteristics of patients with monocarboxylate transporter-8 deficiency: a multicentre retrospective study.
Çelik N, Demir K, Dibeklioğlu SE, et al.
European journal of pediatrics 2024; (184(1)):92 doi:10.1007/s00431-024-05931-7.
PMID: 39699593
15
Tiratricol: First Approval.
Lamb YN
Drugs 2025; (85(8)):1059-1065 doi:10.1007/s40265-025-02197-7.
PMID: 40549098
16
Diagnostic gene sequencing panels: from design to report-a technical standard of the American College of Medical Genetics and Genomics (ACMG).
Bean LJH, Funke B, Carlston CM, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2020; (22(3)):453-461 doi:10.1038/s41436-019-0666-z.
PMID: 31732716
17
Inconsistencies between prenatal diagnostic and genetic testing laboratories on variant validation of rare monogenic diseases.
Lin L, Zhang Y, Pan H, et al.
Prenatal diagnosis 2024; (44(9)):1053-1061 doi:10.1002/pd.6628.
PMID: 38898598
18
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Richards S, Aziz N, Bale S, et al.
Genetics in medicine : official journal of the American College of Medical Genetics 2015; (17(5)):405-24 doi:10.1038/gim.2015.30.
PMID: 25741868
19
Variant reclassification and clinical implications.
Walsh N, Cooper A, Dockery A, O'Byrne JJ
Journal of medical genetics 2024; (61(3)):207-211 doi:10.1136/jmg-2023-109488.
PMID: 38296635

This page explains genetic testing and inheritance for X-linked intellectual disability-hypotonia-movement disorder syndrome for informational purposes only and does not constitute medical advice. A clinical geneticist and your child's care team should interpret the report and discuss monitoring or treatment.

Guide Contents